Global Decentralized Clinical Trials (DCTs) 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI01243308

Publication Date:

January 4, 2024

Pages:

108

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Decentralized Clinical Trials (DCTs) market size was valued at US$ 6979.8 million in 2023. With growing demand in downstream market, the Decentralized Clinical Trials (DCTs) is forecast to a readjusted size of US$ 18970 million by 2030 with a CAGR of 15.4% during review period.
The research report highlights the growth potential of the global Decentralized Clinical Trials (DCTs) market. Decentralized Clinical Trials (DCTs) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Decentralized Clinical Trials (DCTs). 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Decentralized Clinical Trials (DCTs) market.
The FDA defines decentralized clinical trials as those executed through telemedicine and mobile or local healthcare providers, using processes and technologies that differ from the traditional clinical trial model.
Decentralized clinical trials are conducted remotely, with patient subjects remaining at home during a significant portion, or all, of the study. However, the decentralized clinical trial model is designed for more just patient participants.
Global Decentralized Clinical Trials (DCTs) key players include Medidata, IQVIA, Labcorp, PRA Health Sciences, Parexel, etc. Global top five manufacturers hold a share over 45%.
North America is the largest production region, with a share about 60%, followed by Europe and Asia-Pacific, both have a share over 30 percent. In terms of product, Interventional is the largest segment, with a share over 45%. And in terms of application, the largest application is Oncology, followed by Cardiovascular, etc.
Key Features:
The report on Decentralized Clinical Trials (DCTs) market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Decentralized Clinical Trials (DCTs) market. It may include historical data, market segmentation by Type (e.g., Interventional, Observational), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Decentralized Clinical Trials (DCTs) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Decentralized Clinical Trials (DCTs) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Decentralized Clinical Trials (DCTs) industry. This include advancements in Decentralized Clinical Trials (DCTs) technology, Decentralized Clinical Trials (DCTs) new entrants, Decentralized Clinical Trials (DCTs) new investment, and other innovations that are shaping the future of Decentralized Clinical Trials (DCTs).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Decentralized Clinical Trials (DCTs) market. It includes factors influencing customer ' purchasing decisions, preferences for Decentralized Clinical Trials (DCTs) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Decentralized Clinical Trials (DCTs) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Decentralized Clinical Trials (DCTs) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Decentralized Clinical Trials (DCTs) market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Decentralized Clinical Trials (DCTs) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Decentralized Clinical Trials (DCTs) market.
麻豆原创 Segmentation:
Decentralized Clinical Trials (DCTs) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Interventional
Observational
Expanded Access
Segmentation by application
Oncology
Cardiovascular
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Medidata
IQVIA
Labcorp
PRA Health Sciences
Parexel
ICON
Oracle
CRF Health
Clinical Ink
Medable
Science 37

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Decentralized Clinical Trials (DCTs) 麻豆原创 Size 2019-2030
2.1.2 Decentralized Clinical Trials (DCTs) 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Decentralized Clinical Trials (DCTs) Segment by Type
2.2.1 Interventional
2.2.2 Observational
2.2.3 Expanded Access
2.3 Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Type
2.3.1 Decentralized Clinical Trials (DCTs) 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Decentralized Clinical Trials (DCTs) 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Decentralized Clinical Trials (DCTs) Segment by Application
2.4.1 Oncology
2.4.2 Cardiovascular
2.4.3 Others
2.5 Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Application
2.5.1 Decentralized Clinical Trials (DCTs) 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Decentralized Clinical Trials (DCTs) 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Player
3.1 Decentralized Clinical Trials (DCTs) 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Decentralized Clinical Trials (DCTs) Revenue by Players (2019-2024)
3.1.2 Global Decentralized Clinical Trials (DCTs) Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Decentralized Clinical Trials (DCTs) Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Decentralized Clinical Trials (DCTs) by Regions
4.1 Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Decentralized Clinical Trials (DCTs) 麻豆原创 Size Growth (2019-2024)
4.3 APAC Decentralized Clinical Trials (DCTs) 麻豆原创 Size Growth (2019-2024)
4.4 Europe Decentralized Clinical Trials (DCTs) 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Decentralized Clinical Trials (DCTs) 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Country (2019-2024)
5.2 Americas Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Type (2019-2024)
5.3 Americas Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Region (2019-2024)
6.2 APAC Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Type (2019-2024)
6.3 APAC Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Decentralized Clinical Trials (DCTs) by Country (2019-2024)
7.2 Europe Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Type (2019-2024)
7.3 Europe Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Decentralized Clinical Trials (DCTs) by Region (2019-2024)
8.2 Middle East & Africa Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Decentralized Clinical Trials (DCTs) 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.1 Global Decentralized Clinical Trials (DCTs) Forecast by Regions (2025-2030)
10.1.1 Global Decentralized Clinical Trials (DCTs) Forecast by Regions (2025-2030)
10.1.2 Americas Decentralized Clinical Trials (DCTs) Forecast
10.1.3 APAC Decentralized Clinical Trials (DCTs) Forecast
10.1.4 Europe Decentralized Clinical Trials (DCTs) Forecast
10.1.5 Middle East & Africa Decentralized Clinical Trials (DCTs) Forecast
10.2 Americas Decentralized Clinical Trials (DCTs) Forecast by Country (2025-2030)
10.2.1 United States Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.2.2 Canada Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.2.3 Mexico Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.2.4 Brazil Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.3 APAC Decentralized Clinical Trials (DCTs) Forecast by Region (2025-2030)
10.3.1 China Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.3.2 Japan Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.3.3 Korea Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.3.4 Southeast Asia Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.3.5 India Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.3.6 Australia Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.4 Europe Decentralized Clinical Trials (DCTs) Forecast by Country (2025-2030)
10.4.1 Germany Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.4.2 France Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.4.3 UK Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.4.4 Italy Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.4.5 Russia Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.5 Middle East & Africa Decentralized Clinical Trials (DCTs) Forecast by Region (2025-2030)
10.5.1 Egypt Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.5.2 South Africa Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.5.3 Israel Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.5.4 Turkey Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.5.5 GCC Countries Decentralized Clinical Trials (DCTs) 麻豆原创 Forecast
10.6 Global Decentralized Clinical Trials (DCTs) Forecast by Type (2025-2030)
10.7 Global Decentralized Clinical Trials (DCTs) Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Medidata
11.1.1 Medidata Company Information
11.1.2 Medidata Decentralized Clinical Trials (DCTs) Product Offered
11.1.3 Medidata Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Medidata Main Business Overview
11.1.5 Medidata Latest Developments
11.2 IQVIA
11.2.1 IQVIA Company Information
11.2.2 IQVIA Decentralized Clinical Trials (DCTs) Product Offered
11.2.3 IQVIA Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 IQVIA Main Business Overview
11.2.5 IQVIA Latest Developments
11.3 Labcorp
11.3.1 Labcorp Company Information
11.3.2 Labcorp Decentralized Clinical Trials (DCTs) Product Offered
11.3.3 Labcorp Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Labcorp Main Business Overview
11.3.5 Labcorp Latest Developments
11.4 PRA Health Sciences
11.4.1 PRA Health Sciences Company Information
11.4.2 PRA Health Sciences Decentralized Clinical Trials (DCTs) Product Offered
11.4.3 PRA Health Sciences Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 PRA Health Sciences Main Business Overview
11.4.5 PRA Health Sciences Latest Developments
11.5 Parexel
11.5.1 Parexel Company Information
11.5.2 Parexel Decentralized Clinical Trials (DCTs) Product Offered
11.5.3 Parexel Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Parexel Main Business Overview
11.5.5 Parexel Latest Developments
11.6 ICON
11.6.1 ICON Company Information
11.6.2 ICON Decentralized Clinical Trials (DCTs) Product Offered
11.6.3 ICON Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 ICON Main Business Overview
11.6.5 ICON Latest Developments
11.7 Oracle
11.7.1 Oracle Company Information
11.7.2 Oracle Decentralized Clinical Trials (DCTs) Product Offered
11.7.3 Oracle Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Oracle Main Business Overview
11.7.5 Oracle Latest Developments
11.8 CRF Health
11.8.1 CRF Health Company Information
11.8.2 CRF Health Decentralized Clinical Trials (DCTs) Product Offered
11.8.3 CRF Health Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 CRF Health Main Business Overview
11.8.5 CRF Health Latest Developments
11.9 Clinical Ink
11.9.1 Clinical Ink Company Information
11.9.2 Clinical Ink Decentralized Clinical Trials (DCTs) Product Offered
11.9.3 Clinical Ink Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Clinical Ink Main Business Overview
11.9.5 Clinical Ink Latest Developments
11.10 Medable
11.10.1 Medable Company Information
11.10.2 Medable Decentralized Clinical Trials (DCTs) Product Offered
11.10.3 Medable Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Medable Main Business Overview
11.10.5 Medable Latest Developments
11.11 Science 37
11.11.1 Science 37 Company Information
11.11.2 Science 37 Decentralized Clinical Trials (DCTs) Product Offered
11.11.3 Science 37 Decentralized Clinical Trials (DCTs) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Science 37 Main Business Overview
11.11.5 Science 37 Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.